148 related articles for article (PubMed ID: 25002124)
1. BCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivo.
Li C; Yang Z; Du Y; Tang H; Chen J; Hu D; Fan Z
Clin Cancer Res; 2014 Aug; 20(15):4001-13. PubMed ID: 25002124
[TBL] [Abstract][Full Text] [Related]
2. GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells.
Li C; Du Y; Yang Z; He L; Wang Y; Hao L; Ding M; Yan R; Wang J; Fan Z
Cancer Res; 2016 Mar; 76(5):1273-83. PubMed ID: 26676748
[TBL] [Abstract][Full Text] [Related]
3. BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor.
Li C; Yan R; Yang Z; Wang H; Zhang R; Chen H; Wang J
Oncotarget; 2017 Jul; 8(28):46704-46705. PubMed ID: 28578321
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the oligosaccharide component of alpha3beta1 integrin from human bladder carcinoma cell line T24 and its role in adhesion and migration.
Pocheć E; Lityńska A; Bubka M; Amoresano A; Casbarra A
Eur J Cell Biol; 2006 Jan; 85(1):47-57. PubMed ID: 16373174
[TBL] [Abstract][Full Text] [Related]
5. A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro.
Chen Y; Wang H; Zuo Y; Li N; Ding M; Li C
Cancer Med; 2018 May; 7(5):2064-2077. PubMed ID: 29577645
[TBL] [Abstract][Full Text] [Related]
6. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
7. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
[TBL] [Abstract][Full Text] [Related]
8. Integrin alpha3beta1 expressed by human colon cancer cells is a major carrier of oncodevelopmental carbohydrate epitopes.
Prokopishyn NL; Puzon-McLaughlin W; Takada Y; Laferté S
J Cell Biochem; 1999 Feb; 72(2):189-209. PubMed ID: 10022502
[TBL] [Abstract][Full Text] [Related]
9. Arctigenin anti-tumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis.
Yang S; Ma J; Xiao J; Lv X; Li X; Yang H; Liu Y; Feng S; Zhang Y
Anat Rec (Hoboken); 2012 Aug; 295(8):1260-6. PubMed ID: 22619087
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.
Yoshii H; Ito K; Asano T; Horiguchi A; Hayakawa M; Asano T
Oncol Rep; 2013 Sep; 30(3):1073-80. PubMed ID: 23817592
[TBL] [Abstract][Full Text] [Related]
11. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines.
Laidler P; Gil D; Pituch-Noworolska A; Ciołczyk D; Ksiazek D; Przybyło M; Lityńska A
Acta Biochim Pol; 2000; 47(4):1159-70. PubMed ID: 11996105
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of doxorubicin-monoclonal antibody conjugate on human bladder cancer.
Yu DS; Chu TM; Yeh MY; Chang SY; Ma CP; Han SH
J Urol; 1988 Aug; 140(2):415-21. PubMed ID: 3398165
[TBL] [Abstract][Full Text] [Related]
13. Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth.
Zhang H; Jiang H; Wang W; Gong J; Zhang L; Chen Z; Ding Q
Urol Oncol; 2012; 30(6):920-7. PubMed ID: 21478038
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits epidermal growth factor receptor signaling pathway activation and induces apoptosis in bladder cancer cells in vitro and in vivo.
Chang L; Xiao W; Yang Y; Li H; Xia D; Yu G; Guo X; Guan W; Hu Z; Xu H; Zhuang Q; Ye Z
Urol Oncol; 2014 Jan; 32(1):36.e11-8. PubMed ID: 23948182
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.
Zhang T; Wu K; Ding C; Sun K; Guan Z; Wang X; Hsieh JT; He D; Fan J
Oncotarget; 2015 Nov; 6(35):37782-91. PubMed ID: 26462022
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment.
Azuma H; Takahara S; Horie S; Muto S; Otsuki Y; Katsuoka Y
J Urol; 2003 Jun; 169(6):2372-7. PubMed ID: 12771800
[TBL] [Abstract][Full Text] [Related]
17. ppGalNAc T1 as a potential novel marker for human bladder cancer.
Ding MX; Wang HF; Wang JS; Zhan H; Zuo YG; Yang DL; Liu JY; Wang W; Ke CX; Yan RP
Asian Pac J Cancer Prev; 2012; 13(11):5653-7. PubMed ID: 23317233
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
19. A microfluidic system based on the monoclonal antibody BCMab1 specifically captures circulating tumor cells from bladder cancer patients.
Wang Y; Liu Q; Men T; Liang Y; Niu H; Wang J
J Biomater Sci Polym Ed; 2020 Jun; 31(9):1199-1210. PubMed ID: 32275489
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
